Drug Trial Radar · NCT05562830
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Nov 16, 2022
Primary completion
Feb 26, 2029
Study completion Feb 26, 2029
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This substudy is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new treatment options. Substudy 04A will enroll participants with locally advanced or mUC whose disease is resistant to treatment with programmed cell death-1/ligand 1 (PD-1/L1) inhibitors. The protocol infrastructure will enable the rolling assignment of investigational treatments.
Conditions
- Urothelial Carcinoma
Interventions
Zilovertamab vedotinBiological
Administered via intravenous (IV) infusion on day 1 and day 8 of Q3W cycles
PembrolizumabBiological
Administered via IV infusion on Day 1 of each 6 week cycle.
MK-3120Biological
Administered as an IV infusion on Day 1, Day 15, and Day 29 of each 6 week cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Experienced At Least One Adverse Event (AE)Time frame: Up to approximately 5 years
- Percentage of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to approximately 5 years
- Arm A: Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 2 years
- Arm B: ORR as Assessed by InvestigatorTime frame: Up to approximately 2 years
Locations
28 sites in 11 countries. Site status is shown where the registry gives one.
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 1045)
Orange, California
University of California San Francisco ( Site 1044)
San Francisco, California
Anschutz Cancer Pavilion ( Site 1017)
Aurora, Colorado
University of Chicago Medical Center ( Site 1037)
Chicago, Illinois
Indiana University Melvin and Bren Simon Cancer Center ( Site 1011)
Indianapolis, Indiana
Siteman Cancer Center ( Site 1038)
St Louis, Missouri
Memorial Sloan Kettering Cancer Center ( Site 1031)
New York, New York
Cleveland Clinic-Taussig Cancer Center ( Site 1036)
Cleveland, Ohio
UPMC Hillman Cancer Center ( Site 1014)
Pittsburgh, Pennsylvania
Huntsman Cancer Institute ( Site 1041)
Salt Lake City, Utah
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Site 1952)
Brisbane, Queensland, Australia
Princess Margaret Cancer Centre ( Site 1106)
Toronto, Ontario, Canada
FALP-UIDO ( Site 1151)
Santiago, Region M. de Santiago, Chile
Bradford Hill ( Site 1155)
Santiago, Region M. de Santiago, Chile
Rigshospitalet-Dept. of Oncology ( Site 1701)
Copenhagen, Capital Region, Denmark
Rambam Health Care Campus-Oncology ( Site 1501)
Haifa, Israel
Rabin Medical Center-Oncology ( Site 1504)
Petah Tikva, Israel
Sheba Medical Center-ONCOLOGY ( Site 1503)
Ramat Gan, Israel
Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Sperimentazioni Cliniche ( Site 1406)
Naples, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1408)
Milan, Lombardy, Italy
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 1302)
Amsterdam, North Holland, Netherlands
Severance Hospital, Yonsei University Health System ( Site 1903)
Seoul, South Korea
Asan Medical Center ( Site 1901)
Seoul, South Korea
Samsung Medical Center ( Site 1902)
Seoul, South Korea
Hospital Clinico San Carlos ( Site 1765)
Madrid, Spain
Hospital Universitari Vall d'Hebron ( Site 1767)
Barcelona, Catalonia, Spain
St Bartholomew's Hospital ( Site 1206)
London, London, City of, United Kingdom
ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 1201)
London, London, City of, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.